Gary Nachman
Stock Analyst at Raymond James
(3.75)
# 748
Out of 5,116 analysts
97
Total ratings
58.9%
Success rate
6.31%
Average return
Main Sectors:
Stocks Rated by Gary Nachman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Reiterates: Strong Buy | $85 → $89 | $79.93 | +11.35% | 4 | Oct 30, 2025 | |
| BLCO Bausch + Lomb | Reiterates: Outperform | $18 → $19 | $17.18 | +10.59% | 2 | Oct 30, 2025 | |
| LENZ LENZ Therapeutics | Reiterates: Outperform | $40 → $50 | $16.87 | +196.38% | 3 | Oct 20, 2025 | |
| ABBV AbbVie | Reiterates: Outperform | $236 → $250 | $229.98 | +8.71% | 17 | Oct 17, 2025 | |
| AMGN Amgen | Assumes: Market Perform | n/a | $332.93 | - | 2 | Sep 3, 2025 | |
| VERU Veru Inc. | Maintains: Outperform | $30 → $20 | $2.40 | +733.33% | 2 | Aug 13, 2025 | |
| SDGR Schrödinger | Maintains: Outperform | $25 → $28 | $18.31 | +52.92% | 5 | Nov 13, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $275 → $298 | $400.59 | -25.61% | 7 | Nov 1, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Strong Buy | $20 | $4.49 | +345.93% | 1 | Sep 27, 2024 | |
| PCRX Pacira BioSciences | Maintains: Outperform | $41 → $37 | $26.51 | +39.57% | 13 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $30 | $45.67 | -34.31% | 5 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $5.99 | +16.86% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $170.48 | - | 11 | Sep 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $4 | $12.95 | -69.11% | 5 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $17.56 | +70.84% | 4 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $32 | $3.58 | +793.85% | 1 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $16 → $14 | $12.32 | +13.64% | 2 | Feb 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $11 → $10 | $31.89 | -68.64% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $44.01 | -31.83% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $810 → $750 | $4.07 | +18,327.52% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $8 | $7.20 | +11.11% | 2 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $21 | $27.12 | -22.57% | 5 | May 11, 2020 |
Ionis Pharmaceuticals
Oct 30, 2025
Reiterates: Strong Buy
Price Target: $85 → $89
Current: $79.93
Upside: +11.35%
Bausch + Lomb
Oct 30, 2025
Reiterates: Outperform
Price Target: $18 → $19
Current: $17.18
Upside: +10.59%
LENZ Therapeutics
Oct 20, 2025
Reiterates: Outperform
Price Target: $40 → $50
Current: $16.87
Upside: +196.38%
AbbVie
Oct 17, 2025
Reiterates: Outperform
Price Target: $236 → $250
Current: $229.98
Upside: +8.71%
Amgen
Sep 3, 2025
Assumes: Market Perform
Price Target: n/a
Current: $332.93
Upside: -
Veru Inc.
Aug 13, 2025
Maintains: Outperform
Price Target: $30 → $20
Current: $2.40
Upside: +733.33%
Schrödinger
Nov 13, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $18.31
Upside: +52.92%
Alnylam Pharmaceuticals
Nov 1, 2024
Maintains: Outperform
Price Target: $275 → $298
Current: $400.59
Upside: -25.61%
Achieve Life Sciences
Sep 27, 2024
Initiates: Strong Buy
Price Target: $20
Current: $4.49
Upside: +345.93%
Pacira BioSciences
Jul 31, 2024
Maintains: Outperform
Price Target: $41 → $37
Current: $26.51
Upside: +39.57%
Mar 28, 2024
Initiates: Strong Buy
Price Target: $30
Current: $45.67
Upside: -34.31%
Mar 28, 2024
Initiates: Outperform
Price Target: $7
Current: $5.99
Upside: +16.86%
Sep 29, 2023
Initiates: Market Perform
Price Target: n/a
Current: $170.48
Upside: -
Mar 3, 2023
Maintains: Market Perform
Price Target: $5 → $4
Current: $12.95
Upside: -69.11%
Mar 1, 2023
Maintains: Outperform
Price Target: $35 → $30
Current: $17.56
Upside: +70.84%
Feb 22, 2023
Maintains: Outperform
Price Target: $40 → $32
Current: $3.58
Upside: +793.85%
Feb 17, 2023
Downgrades: Market Perform
Price Target: $16 → $14
Current: $12.32
Upside: +13.64%
Nov 7, 2022
Maintains: Market Perform
Price Target: $11 → $10
Current: $31.89
Upside: -68.64%
Nov 4, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $44.01
Upside: -31.83%
Aug 11, 2022
Maintains: Outperform
Price Target: $810 → $750
Current: $4.07
Upside: +18,327.52%
Aug 10, 2022
Maintains: Market Perform
Price Target: $15 → $8
Current: $7.20
Upside: +11.11%
May 11, 2020
Maintains: Market Perform
Price Target: $20 → $21
Current: $27.12
Upside: -22.57%